Adalimumab-associated pulmonary cryptococcosis

13Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

Abstract

This is the first report of adalimumab-associated pulmonary cryptococcosis. A 56-year-old female with rheumatoid arthritis without a history of pulmonary disease was simultaneously administered adalimumab (40 mg/2 wks), methotrexate (4 mg/wk), and isoniazid (200 mg/ day). Five months later, chest radiography revealed a small spiculated pulmonary nodule, and the laboratory test results, including levels of tumor markers and plasma β-D-glucan, were within normal ranges. Since the lesion continued to grow, even after discontinuing adali-mumab, it was surgically resected. Grocott staining of the tissue sample revealed black-brown fungi, identified as Cryptococcus neoformans in culture. The patient now remains well, without adalimumab therapy. © 2011 The Editorial Committee of Annals of Thoracic and Cardiovascular Surgery. All rights reserved.

Cite

CITATION STYLE

APA

Iwata, T., Nagano, T., Tomita, M., Suehiro, Y., Nakatsuka, S. ichi, Kimura, H., & Sakaki, M. (2011). Adalimumab-associated pulmonary cryptococcosis. Annals of Thoracic and Cardiovascular Surgery, 17(4), 390–393. https://doi.org/10.5761/atcs.cr.10.01561

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free